Home › Research › Treatments
Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause
Henderson VW.. The Journal of steroid biochemistry and molecular biology, 2013-05-28
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Hormonal changes associated with the menopausal transition and postmenopause have the potential to influence processes linked to Alzheimer's disease symptoms and pathogenesis, but effects of menopause on Alzheimer risk can be addressed only indirectly. Nine randomized clinical trials of estrogen-containing hormone therapy in Alzheimer's disease patients were identified by a systematic literature search. Findings suggest that hormone therapy does not improve cognitive symptoms of women with Alzheimer's disease. No clinical trials of hormone therapy address Alzheimer prevention, but one clinical trial provides moderate evidence that continuous, combined estrogen plus progestogen initiated at age 65 years or older increases the risk of dementia. The timing, or critical window, hypothesis suggests that hormone therapy initiated at a younger age in closer temporal proximity to menopause may reduce the risk of Alzheimer's disease. This hypothesis is supported by observational research but is not addressed by clinical trial data. Unrecognized confounding is of concern in interpreting observational results, and research that helps resolve this issue will have important public health implications. Well-designed cohort studies, convergent evidence from appropriate laboratory models, and long-term clinical trials using surrogate biomarkers of brain function and neural pathology could provide relevant answers. Other estrogenic compounds are of theoretical interest with respect to Alzheimer treatment and risk. Effects of selective estrogen receptor modulators such as raloxifene may differ from those of estrogens; potential effects of phytoestrogens are not well studied. This article is part of a Special Issue entitled 'Menopause'.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study. Across nine randomized trials, estrogen-containing hormone therapy did not improve cognitive symptoms in women who already had Alzheimer's disease. One trial found that combined estrogen plus progestogen started at age 65 or older increased dementia risk, while the idea that starting hormone therapy closer to menopause might reduce risk comes only from observational research and has not been tested in clinical trials.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Henderson, V. W. (2014). Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. The Journal of steroid biochemistry and molecular biology. https://doi.org/10.1016/j.jsbmb.2013.05.010
Vancouver
Henderson VW. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. The Journal of steroid biochemistry and molecular biology. 2014. doi:10.1016/j.jsbmb.2013.05.010. PMID: 23727128.
BibTeX
@article{henderson2014-23727128,
author = {Henderson, V. W.},
title = {{Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause}},
journal = {The Journal of steroid biochemistry and molecular biology},
year = {2014},
doi = {10.1016/j.jsbmb.2013.05.010},
pmid = {23727128},
url = {https://doi.org/10.1016/j.jsbmb.2013.05.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Hormonal changes associated with the menopausal transition and postmenopause have the potential to influence processes linked to Alzheimer's disease symptoms and pathogenesis, but effects of menopause on Alzheimer risk can be addressed only indirectly.
- Findings suggest that hormone therapy does not improve cognitive symptoms of women with Alzheimer's disease.
- The timing, or critical window, hypothesis suggests that hormone therapy initiated at a younger age in closer temporal proximity to menopause may reduce the risk of Alzheimer's disease.
- Unrecognized confounding is of concern in interpreting observational results, and research that helps resolve this issue will have important public health implications.
Why it matters
Across nine randomized trials, estrogen-containing hormone therapy did not improve cognitive symptoms in women who already had Alzheimer's disease. One trial found that combined estrogen plus progestogen started at age 65 or older increased dementia risk, while the idea that starting hormone therapy closer to menopause might reduce risk comes only from observational research and has not been tested in clinical trials.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcohort study
- Evidence strengthHigh
How this study scored 56/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of steroid biochemistry and molecular biology) |
| Journal's citation record | 2 / 4 | The Journal of Steroid Biochemistry and Molecular Biology: journal h-index 189 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 180 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.9 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 4 / 6 | Cited 8.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 36 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Victor W. Henderson: h-index 79 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23727128) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jsbmb.2013.05.010
- PubMed: 23727128
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also in Treatments
203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.